UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting next-generation PDE4 inhibitors in search of potential management of rheumatoid arthritis and psoriasis

Bioorganic chemistry, 2024-10, Vol.151, p.107689, Article 107689

2024

Volltextzugriff (PDF)

Beyond PDE4 inhibition: A comprehensive review on downstream cAMP signaling in the central nervous system

Biomedicine & pharmacotherapy, 2024-08, Vol.177, p.117009, Article 117009

2024

Volltextzugriff (PDF)

The Psoriasis Treatment Pipeline: An Overview and Update

Dermatologic clinics, 2024-07, Vol.42 (3), p.365-375

2024

Volltextzugriff (PDF)

Targeting Aquaporin-5 by Phosphodiesterase 4 Inhibition Offers New Therapeutic Opportunities for Ovarian Ischemia Reperfusion Injury in Rats

Reproductive sciences (Thousand Oaks, Calif.), 2024-07, Vol.31 (7), p.2021-2031

2024

Volltextzugriff (PDF)

GNAS mutation inhibits growth and induces phosphodiesterase 4D expression in colorectal cancer cell lines

International journal of cancer, 2024-06, Vol.154 (11), p.1987-1998

2024

Volltextzugriff (PDF)

Altered Expression of PDE4 Genes in Schizophrenia: Insights from a Brain and Blood Sample Meta-Analysis and iPSC-Derived Neurons

Genes, 2024-05, Vol.15 (5), p.609

2024

Volltextzugriff (PDF)

Vitiligo non‐responding lesions to narrow band UVB have intriguing cellular and molecular abnormalities that may prevent epidermal repigmentation

Pigment cell and melanoma research, 2024-05, Vol.37 (3), p.378-390

2024

Volltextzugriff (PDF)

Functional rescue of CFTR in rectal organoids from patients carrying R334W variant by CFTR modulators and PDE4 inhibitor Roflumilast

Respiratory investigation, 2024-05, Vol.62 (3), p.455-461

2024

Volltextzugriff (PDF)

Safety, Tolerability, and Pharmacokinetics of a Novel Oral Phosphodiesterase 4 Inhibitor, ME3183: First‐in‐Human Phase 1 Study

Clinical pharmacology in drug development, 2024-04, Vol.13 (4), p.341-348

2024

Volltextzugriff (PDF)

Urinary liver‐type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone‐induced acute kidney injury

Nephrology (Carlton, Vic.), 2024-03, Vol.29 (3), p.117-125

2024

Volltextzugriff (PDF)

Vesicle-Encapsulated Rolipram (PDE4 Inhibitor) and Its Anticancer Activity

ACS applied bio materials, 2024-01, Vol.7 (1), p.369-378

2024

Volltextzugriff (PDF)

New quinoline-based PDE4 inhibitors through GSK-256066 fragment-based elaboration

Journal of molecular structure, 2024-01, Vol.1295, p.136719, Article 136719

2024

Volltextzugriff (PDF)

PDE4 Phosphodiesterases in Cardiovascular Diseases: Key Pathophysiological Players and Potential Therapeutic Targets

International journal of molecular sciences, 2023-12, Vol.24 (23), p.17017

2023

Volltextzugriff (PDF)

Roflumilast ameliorates ovariectomy-induced depressive-like behavior in rats via activation of AMPK/mTOR/ULK1-dependent autophagy pathway

Life sciences (1973), 2023-08, Vol.327, p.121806-121806, Article 121806

2023

Volltextzugriff (PDF)

Phosphodiesterase-4 Inhibition in Parkinson’s Disease: Molecular Insights and Therapeutic Potential

Cellular and molecular neurobiology, 2023-08, Vol.43 (6), p.2713-2741

2023

Volltextzugriff (PDF)

PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes

International journal of molecular sciences, 2023-07, Vol.24 (14), p.11518

2023

Volltextzugriff (PDF)

FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes

Journal of cystic fibrosis, 2023-05, Vol.22 (3), p.548-559

2023

Volltextzugriff (PDF)

Sappanone A: A natural PDE4 inhibitor with dual anti-inflammatory and antioxidant activities from the heartwood of Caesalpinia sappan L

Journal of ethnopharmacology, 2023-03, Vol.304, p.116020-116020, Article 116020

2023

Volltextzugriff (PDF)

Advances in the development of phosphodiesterase-4 inhibitors

European journal of medicinal chemistry, 2023-03, Vol.250, p.115195-115195, Article 115195

2023

Volltextzugriff (PDF)

Acute PDE4 Inhibition Induces a Transient Increase in Blood Glucose in Mice

International journal of molecular sciences, 2023-02, Vol.24 (4), p.3260

2023

Volltextzugriff (PDF)

BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF)

Expert opinion on investigational drugs, 2023-01, Vol.32 (1), p.17-23

2023

Volltextzugriff (PDF)

ZL-n-91, a specific Phosphodiesterase-4 inhibitor, suppresses the growth of triple-negative breast cancer

Investigational new drugs, 2022-10, Vol.40 (5), p.875-883

2022

Volltextzugriff (PDF)

The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches

International journal of molecular sciences, 2022-09, Vol.23 (18), p.10616

Lugnier, Claire

2022

Volltextzugriff (PDF)

An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022

Molecules (Basel, Switzerland), 2022-08, Vol.27 (15), p.4964

2022

Volltextzugriff (PDF)

Phosphodiesterase type 4 anchoring regulates cAMP signaling to Popeye domain-containing proteins

Journal of molecular and cellular cardiology, 2022-04, Vol.165, p.86-102

2022

Volltextzugriff (PDF)

1 – 25 von 374

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(366)
Mit Volltextzugriff
(334)

Publikationsform

Artikel
(370)
Buchkapitel
(4)

Sprache

Englisch
(374)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(368)
Humans
(227)
Animals
(226)
Pharmacology & Pharmacy
(203)
Pde4
(186)
Cyclic Nucleotide Phosphodiesterases, Type 4 - Metabolism
(128)
Male
(116)
Cyclic Nucleotide Phosphodiesterases, Type 4
(109)
Rats
(106)
Phosphodiesterase 4 Inhibitors - Pharmacology
(105)
Chemistry, Medicinal
(95)
Biological And Medical Sciences
(92)
Medical Sciences
(83)
Chemistry
(81)
Physical Sciences
(81)
Phosphodiesterase
(78)
Phosphodiesterase Inhibitors - Pharmacology
(77)
Pharmacology. Drug Treatments
(75)
Mice
(74)

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Targeting next-generation PDE4 inhibitors in search of potential management of rheumatoid arthritis and psoriasis

Beyond PDE4 inhibition: A comprehensive review on downstream cAMP signaling in the central nervous system

The Psoriasis Treatment Pipeline: An Overview and Update

Targeting Aquaporin-5 by Phosphodiesterase 4 Inhibition Offers New Therapeutic Opportunities for Ovarian Ischemia Reperfusion Injury in Rats

GNAS mutation inhibits growth and induces phosphodiesterase 4D expression in colorectal cancer cell lines

Altered Expression of PDE4 Genes in Schizophrenia: Insights from a Brain and Blood Sample Meta-Analysis and iPSC-Derived Neurons

Vitiligo non‐responding lesions to narrow band UVB have intriguing cellular and molecular abnormalities that may prevent epidermal repigmentation

Functional rescue of CFTR in rectal organoids from patients carrying R334W variant by CFTR modulators and PDE4 inhibitor Roflumilast

Safety, Tolerability, and Pharmacokinetics of a Novel Oral Phosphodiesterase 4 Inhibitor, ME3183: First‐in‐Human Phase 1 Study

Urinary liver‐type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone‐induced acute kidney injury

Vesicle-Encapsulated Rolipram (PDE4 Inhibitor) and Its Anticancer Activity

New quinoline-based PDE4 inhibitors through GSK-256066 fragment-based elaboration

PDE4 Phosphodiesterases in Cardiovascular Diseases: Key Pathophysiological Players and Potential Therapeutic Targets

Roflumilast ameliorates ovariectomy-induced depressive-like behavior in rats via activation of AMPK/mTOR/ULK1-dependent autophagy pathway

Phosphodiesterase-4 Inhibition in Parkinson’s Disease: Molecular Insights and Therapeutic Potential

PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes

FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes

Sappanone A: A natural PDE4 inhibitor with dual anti-inflammatory and antioxidant activities from the heartwood of Caesalpinia sappan L

Advances in the development of phosphodiesterase-4 inhibitors

Acute PDE4 Inhibition Induces a Transient Increase in Blood Glucose in Mice

BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF)

ZL-n-91, a specific Phosphodiesterase-4 inhibitor, suppresses the growth of triple-negative breast cancer

The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches

An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022

Phosphodiesterase type 4 anchoring regulates cAMP signaling to Popeye domain-containing proteins

Aktive Filter

Suchergebnisse filtern